Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH–Peptide Conjugates
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25021095 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ildikó Szabó und 9 weiteren Autor:innen. Beteiligte Einrichtung: HUN-REN-ELTE Research Group of Peptide Chemistry, 1117 Budapest, Hungary. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office, National Laboratories Excellence program, Hungarian Thematic Excellence Program.
Abstract (Originalsprache)
Malignant melanoma is one of the most aggressive and resistant tumor types, with high metastatic properties. Because of the lack of suitable chemotherapeutic agents for treatment, the 5-year survival rate of melanoma patients with regional and distant metastases is lower than 10%. Targeted tumor therapy that provides several promising results might be a good option for the treatment of malignant melanomas. Our goal was to develop novel melanoma-specific peptide–drug conjugates for targeted tumor therapy. Melanocortin-1-receptor (MC1R) is a cell surface receptor responsible for melanogenesis and it is overexpressed on the surface of melanoma cells, providing a good target. Its native ligand, α-MSH (α-melanocyte-stimulating hormone) peptide, or its derivatives, might be potential homing devices for this purpose. Therefore, we prepared three α-MSH derivative–daunomycin (Dau) conjugates and their in vitro and in vivo antitumor activities were compared. Dau has an autofluorescence property; therefore, it is suitable for preparing conjugates for in vitro (e.g., cellular uptake) and in vivo experiments. Dau was attached to the peptides via a non-cleavable oxime linkage that was applied efficiently in our previous experiments, resulting in conjugates with high tumor growth inhibition activity. The results indicated that the most promising conjugate was the compound in which Dau was connected to the side chain of Lys (Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2). The highest cellular uptake by melanoma cells was demonstrated using the compound, with the highest tumor growth inhibition detected both on mouse (38.6% on B16) and human uveal melanoma (55% on OMC-1) cells. The effect of the compound was more pronounced than that of the free drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HUN-REN-ELTE Research Group of Peptide Chemistry, 1117 Budapest, Hungary.
- MTA-TTK "Momentum" Peptide-Based Vaccines Research Group, Institute of Materials and Environmental Chemistry, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary.
- National Tumor Biology Laboratory, Department of Experimental Pharmacology, National Institute of Oncology, 1122 Budapest, Hungary.
- School of Ph.D. Studies, Doctoral School of Pathological Sciences, Semmelweis University, 1085 Budapest, Hungary.
- Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
ORCID-Profile: Ildikó Szabó, Beáta Biri-Kovács
Förderung
- National Research, Development and Innovation Office
- National Laboratories Excellence program
- Hungarian Thematic Excellence Program
- Marie Skłodowska-Curie Action ETN
- National Research, Development and Innovation Fund of Hungary
- theNew National Excellence Program Bolyai+
- János Bolyai research grant of the Hungarian Academy of Sciences
- European Union′s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Action ITN
Zitieren
APA
Szabó, I., Biri-Kovács, B., Vári, B., Ranđelović, I., Vári-Mező, D., Juhász, É., Halmos, G., Bősze, S., Tóvári, J., & Mező, G. (2024). Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH–Peptide Conjugates. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25021095
Vancouver
Szabó I, Biri-Kovács B, Vári B, Ranđelović I, Vári-Mező D, Juhász É, et al. Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH–Peptide Conjugates. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25021095
BibTeX
@article{Szab2024,
author = {Szabó, Ildikó and Biri-Kovács, Beáta and Vári, Balázs and Ranđelović, Ivan and Vári-Mező, Diána and Juhász, Éva and Halmos, Gábor and Bősze, Szilvia and Tóvári, József and Mező, Gábor},
title = {Targeting the Melanocortin 1 Receptor in Melanoma: Biological Activity of α-MSH–Peptide Conjugates},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25021095}
}
EUVIMED